Our time at #ASCO26 reaffirmed why we do this work — alongside clinicians, scientists and partners committed to better outcomes for patients with cancer. At Aulos, our focus remains steady: building on the new Phase 2 data we shared for imneskibart in doublet checkpoint inhibitor-refractory metastatic melanoma, and continuing to advance this selective immune-activating therapy in additional checkpoint inhibitor-refractory tumors, including non-small cell lung cancer. Thank you to the investigators, clinical teams and patients whose participation makes this progress possible. #CancerResearch #Immunotherapy

New Phase 2 data at #ASCO26: 33% objective response rate and 67% disease control rate in doublet checkpoint inhibitor-refractory metastatic melanoma patients treated with the imneskibart triplet regimen. Read the data: bit.ly/4dIAABT #ASCO26 #Immunotherapy #CancerResearch #IL2

At the @ASCO Annual Meeting, Aulos is presenting Phase 1/2 data for imneskibart in doublet checkpoint inhibitor-refractory cutaneous melanoma — a setting with limited options for patients following tumor progression on anti–PD-1/anti–CTLA-4 or anti–PD-1/anti–LAG-3 combinations. We’re excited to share our findings with the oncology community. Learn more: bit.ly/4sNEEWW #ASCO2026 #Melanoma #ImmunoOncology #Biotech #medex

The imneskibart story extends beyond the tumor microenvironment. Selective IL-2 engagement is designed to maintain immune activation while limiting toxicities — including vascular leak syndrome and pulmonary edema — that have historically constrained this pathway. Learn more: aulosbio.com/our-approach/ #CancerEducation #ImmunoOncology #MedEd

The #TumorMicroenvironment (TME) plays a powerful role in cancer progression and treatment response. At Aulos, we're exploring innovative therapies to effectively modulate the TME, enhancing immune responses against tumors. Learn more about our approach: aulosbio.com/our-approach/ #CancerEducation #ImmunoOncology

The 2025 #NobelPrize in Medicine honors the scientists who discovered immunosuppressive regulatory T cells (Tregs) — a breakthrough that reshaped immunology. Imneskibart builds on this legacy by activating Teffs & NK cells while limiting Tregs in solid tumor cancers.   #Immunotherapy #Tregs #CancerResearch

This Thanksgiving, we’re grateful for the patients, families, investigators and clinical teams who make progress in immuno-oncology possible. Your trust and commitment drive every step forward.   Thank you.   #Thanksgiving

Aulos is featured in @DDWJournal’s “One to Watch” spotlight.   CEO Aron Knickerbocker explains how imneskibart was designed to minimize the challenges of immune activation, while driving durable tumor reductions in #melanoma, #NSCLC and other tumor types.   Read more: ddw-online.com/one-to-watch-…   #CancerResearch #Immunotherapy

CEO Aron Knickerbocker spoke with BiotechTV at #SITC2025 about the latest Phase 2 imneskibart data — showing responses in #melanoma and #LungCancer, and higher Teff/Treg ratios that may correlate with longer time on treatment and overall survival for patients.  Watch here: biotechtv.com/post/aulos-bio…   #CancerResearch #Immunotherapy

Grateful for the science and collaboration that defined #SITC2025.    As we head into the final months of 2025, we’re moving forward with the same purpose: advancing imneskibart and the promise of this selective immune-activating therapy for patients.    Learn more about Aulos: bit.ly/4p8hmcZ   #CancerResearch #Immunotherapy

At #SITC2025, we’re spotlighting the convergence of science and technology driving selective IL-2 innovation. Imneskibart shows what’s possible when precision design meets real-world oncology needs.   Learn more: bit.ly/4nOY7nL   #Cytokines #AIinHealthcare #Biotech

Ahead of #SITC2025: Explore how selective IL-2 biology can help the immune system do what it does best—fight cancer with precision.   Learn more about our work: aulosbio.com/our-approach/   #Immunotherapy #CancerResearch

Listen as CEO Aron Knickerbocker discusses the promising clinical progress of imneskibart and our focus on patient safety: bit.ly/4oDfoSE #CancerResearch

Cytokines are immune messengers that activate tumor-fighting cells. At Aulos, we're precisely directing IL-2 for stronger, targeted responses. Learn more: aulosbio.com/our-approach/ #Immunotherapy #CancerResearch

#News: We’re sharing updated Phase 2 data for imneskibart (AU-007) in checkpoint inhibitor (CPI)-refractory #melanoma & #NSCLC at #SITC25. Learn more: bit.ly/431qEia #Immunotherapy #CancerResearch

Today we honor cancer research innovation. At Aulos, we’ve leveraged machine learning along with immunology expertise to advance a precise immunotherapy, imneskibart (AU-007). #WorldCancerResearchDay #CancerResearch

Hear how AI played a key role in helping design imneskibart, our IL-2 antibody candidate, from CEO Aron Knickerbocker: bit.ly/4oDfoSE #AIinHealthcare

What have we learned about #IL2? It boosts immune cells to fight tumors—but also activates regulatory T cells (Tregs), which suppress immune responses. Effective IL-2 therapy requires precisely targeting the right cells and avoiding unwanted suppression. Learn more: aulosbio.com/about-us/ #CancerScience #ImmunoOncology #MedEd

The @WHO has assigned an International Nonproprietary Name to our investigational IL-2 antibody: imneskibart (AU-007). What’s next: We’re continuing to advance imneskibart in oncology clinical development and look forward to sharing updates on our progress. #Immunotherapy #Biotech #CancerResearch

Missed it? Aron Knickerbocker shares how Aulos safely targets IL-2 to boost cancer-fighting immune cells without toxicity. Listen here: bit.ly/4oDfoSE #CancerResearch #Podcast